CINECA IRIS Institutional Research Information System

DEL RE, MARZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.967
AS - Asia 6.153
EU - Europa 4.690
SA - Sud America 1.136
AF - Africa 373
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 24.353
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.666
SG - Singapore 2.114
IT - Italia 1.869
CN - Cina 1.502
HK - Hong Kong 1.063
BR - Brasile 919
VN - Vietnam 595
SE - Svezia 576
DE - Germania 407
GB - Regno Unito 406
BG - Bulgaria 302
FR - Francia 266
CA - Canada 181
FI - Finlandia 174
CI - Costa d'Avorio 157
RU - Federazione Russa 157
IN - India 153
JP - Giappone 147
TR - Turchia 133
AT - Austria 132
NL - Olanda 105
AR - Argentina 81
BD - Bangladesh 80
PL - Polonia 68
KR - Corea 62
SN - Senegal 61
MX - Messico 56
IQ - Iraq 49
ZA - Sudafrica 47
ES - Italia 45
ID - Indonesia 33
UA - Ucraina 32
BE - Belgio 31
PK - Pakistan 31
SA - Arabia Saudita 31
VE - Venezuela 30
EC - Ecuador 28
MA - Marocco 24
NG - Nigeria 23
UZ - Uzbekistan 23
CO - Colombia 21
AU - Australia 18
CH - Svizzera 17
LT - Lituania 17
KE - Kenya 15
PH - Filippine 15
UY - Uruguay 15
CZ - Repubblica Ceca 13
PY - Paraguay 13
RO - Romania 12
TW - Taiwan 12
CR - Costa Rica 11
CL - Cile 10
IL - Israele 10
JM - Giamaica 10
JO - Giordania 10
PE - Perù 10
EU - Europa 9
KZ - Kazakistan 9
MY - Malesia 9
NP - Nepal 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
IE - Irlanda 8
TN - Tunisia 8
TT - Trinidad e Tobago 8
AL - Albania 7
AZ - Azerbaigian 7
DO - Repubblica Dominicana 7
LB - Libano 7
PA - Panama 7
EG - Egitto 6
SV - El Salvador 6
DK - Danimarca 5
ET - Etiopia 5
LV - Lettonia 5
NO - Norvegia 5
PT - Portogallo 5
TH - Thailandia 5
BJ - Benin 4
GH - Ghana 4
GT - Guatemala 4
HR - Croazia 4
HU - Ungheria 4
IR - Iran 4
LK - Sri Lanka 4
NZ - Nuova Zelanda 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BF - Burkina Faso 3
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
GE - Georgia 3
GR - Grecia 3
KW - Kuwait 3
LU - Lussemburgo 3
RS - Serbia 3
SY - Repubblica araba siriana 3
Totale 24.312
Salva come PNG Salva come JPEG
Città #
Ashburn 1.337
Singapore 1.098
Hong Kong 1.045
Fairfield 906
Woodbridge 878
Dallas 857
Santa Clara 786
Houston 622
San Jose 621
Ann Arbor 584
Chandler 548
Serra 434
Shanghai 421
Seattle 401
Wilmington 319
Sofia 300
New York 293
Beijing 284
Boardman 265
Cambridge 264
London 241
Los Angeles 216
Florence 181
Pisa 177
Princeton 177
Ho Chi Minh City 165
Abidjan 157
Lawrence 148
Lauterbourg 141
Tokyo 122
Medford 121
Vienna 119
Milan 108
Ottawa 106
Hanoi 103
Council Bluffs 100
Munich 97
Frankfurt am Main 89
Hefei 88
São Paulo 82
Redondo Beach 69
Istanbul 68
Rome 66
San Diego 66
Buffalo 65
Dearborn 62
Warsaw 62
Dakar 61
Des Moines 60
Nanjing 60
Helsinki 58
Dong Ket 52
Seoul 52
Turku 52
Turin 46
Rio de Janeiro 43
Bremen 39
Ogden 39
Nuremberg 37
Boulder 33
Cascina 32
Phoenix 32
Chicago 30
Izmir 28
Redwood City 28
Da Nang 27
Orem 27
Brussels 24
Fuzhou 24
Kunming 24
Toronto 24
Düsseldorf 23
Lagos 23
Montreal 23
Paris 22
Washington 22
Denver 21
Tashkent 21
Brasília 20
Chennai 20
Guangzhou 19
Livorno 19
Nanchang 19
Naples 19
Stockholm 19
Baghdad 18
Changsha 18
Mumbai 18
San Francisco 18
Belo Horizonte 17
Brooklyn 17
Columbus 17
Johannesburg 17
Amsterdam 16
Hyderabad 16
Jacksonville 16
Mexico City 16
Quanzhou 16
Dhaka 15
Haiphong 15
Totale 16.931
Salva come PNG Salva come JPEG
Nome #
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer 448
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 323
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 298
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 248
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 214
Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. 212
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 209
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 207
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 203
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 201
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 199
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 198
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 197
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 193
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 192
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 191
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 188
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 187
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients 183
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 182
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 181
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 179
EGFR signaling pathway as therapeutic target in human cancers 179
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 178
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 178
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro 178
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 177
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 177
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 177
Clinical pharmacology of intravitreal anti-VEGF drugs 176
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 176
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 175
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 175
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 174
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence 174
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 173
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 173
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 171
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 170
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 169
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 169
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 168
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors 168
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 167
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial 165
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 165
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 165
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 163
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 160
Author's reply. 157
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 157
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 156
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 156
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment 155
Pharmacogenetics of anti-estrogen treatment of breast cancer 153
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? 152
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 152
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 152
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 152
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 152
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 150
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 148
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: A lethal case with a new variant 148
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 147
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 146
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 146
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. 145
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 145
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 144
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 143
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 142
null 142
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 142
Genome Wide Association Studies (GWAS) 141
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 141
Radiomics and liquid biopsy in oncology: the holons of systems medicine 140
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 138
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 138
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 135
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 135
Genetic variation: effect on prostate cancer 132
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 132
Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position 132
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC 132
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 132
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients 131
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 130
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors 129
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? 128
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 126
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer 125
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 125
Nicotine Metabolite Ratio in Smokers: A Real World Experience 125
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele 124
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 124
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 124
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 123
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 122
Totale 16.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021260 0 0 0 0 0 0 0 0 0 0 88 172
2021/20221.514 18 46 22 36 237 269 95 74 100 96 93 428
2022/20232.415 299 323 170 170 193 287 33 156 499 25 230 30
2023/20241.704 99 112 263 81 171 327 96 73 40 85 142 215
2024/20255.838 94 205 69 256 579 649 466 333 630 732 645 1.180
2025/20267.001 498 918 907 953 707 514 1.035 334 396 572 167 0
Totale 24.894